BibTex RIS Kaynak Göster

HLA Doku Uygunluk Kompleksi,Genetik Lokalizasyonları ve Fonksiyonları

Yıl 2004, Cilt: 2 Sayı: 1, 53 - 57, 01.03.2004

Tahsin Yakut

Öz

Çocukluk çağında görülen birçok otoimmun, allerjik, infeksiyon yada çeflitli malign hastalıklarda, hastalığın seyri açısından bireyler arasında belirgin farklılıkların olduğu bilinmektedir. Bu farklılıkların hastalığı oluşturan etkenlerle ilgili olduğu gibi, bireylerin HLA doku uygunluk antijenlerinin yarattığı cevabın farklılığını oluşturan genetik çeşitlilikle de ilgili olduğu ortaya çıkmıştır.

Kaynakça

  • 1. Lobo PI, Spencer CE, Isaacs RB, McCullough C. Hyperacute renal allograft rejection from anti-HLA class 1 antibody to B cells--antibody detection by two color FCXM was possible only after using pronase-digested donor lymphocytes. Transpl Int 1997; 10:69-73.
  • 2. Ikuta Y, Katayama N, Wang L, Okugawa T, Takahashi Y, Schmitt M, Gu X, Watanabe M, Akiyoshi K, Nakamura H, Kuribayashi K, Sunamoto J, Shiku H. Presentation of a major histocompatibility complex class 1-binding peptide by monocyte-derived dendritic cells incorporating hydrophobized polysaccharide-truncated HER2 protein complex: implications for a polyvalent immuno-cell therapy. Blood 2002; 99: 3717-24.
  • 3. Dissanayake SK, Thompson JA, Bosch JJ, Clements VK, Chen PW, Ksander BR, Ostrand-Rosenberg S. Activation of tumor-specific CD4(+) T lymphocytes by major histocompatibility complex class II tumor cell vaccines: a novel cell-based immunotherapy. Cancer Res 2004; 64:1867-74.
  • 4. Abbas AK, Lichtman JS. Celluler and molecular immunology. W.B.Saunders, USA. 2nd. edition, 1994; p: 102-14.
  • 5. Doytchinova IA, Guan P, Flower DR. Identifiying human MHC supertypes using bioinformatic methods. J Immunol 2004; 172: 4314-23.
  • 6. Stites DP, Terr AI. Basic and clinical immunology. Stanford, California, 1991.
  • 7. Bainbridge DR, Ellis SA, Sargent IL. HLA-G suppresses proliferation of CD4(+) T-lymphocytes. J Reprod Immunol 2000; 48:17-26.
  • 8. Kim YK, Oh SY, Oh HB, Lee BJ, Son JW, Cho SH, Kim YY, Min KU. Positive association between HLA-DRB1*07 and specific IgE responses to purified major allergens of D. pteronyssinus (Der p 1 and Der p 2). Ann Allergy Asthma Immunol 2002; 88: 170-4.
  • 9. Kudva YC, Deng YJ, Govindarajan R, Abraham RS, Marietta EV, Notkins AL, David CS. HLA-DQ8 transgenic and NOD mice recognize different epitopes within the cytoplasmic region of the tyrosine phosphatase-like molecule, IA-2. Hum Immunol 2001; 62: 1099-105.
  • 10. Weber DA, Dao CT, Jun J, Wigal JL, Jensen PE. Transmembrane domain-mediated colocalization of HLA-DM and HLA-DR is required for optimal HLA-DM catalytic activity. J Immunol 2001; 167: 5167-74.
  • 11. Roitt IM, Jonathan B, Davis MK. Immunology, London, UK, 1993.
  • 12. Matsuzaka Y, Makino S, Nakajima K, Tomizawa M, Oka A, Bahram S, Kulski JK, Tamiya G, Inoko H. New polymorphic microsatellite markers in the human MHC class III region. Tissue Antigens 2001; 57: 397-404.
  • 13. Milner CM, Campbell RD. Genetic organization of the human MHC class III region. Front Biosci 2001; 6 : 914-26.
  • 14. Kostyu DD, Hannick LI, Traweek JL, Ghanayem M, Heilpern D, Dawson DV. HLA class I polymorphism: structure and function and still questions. Hum Immunol 1997: 571: 1- 18.
  • 15. Birol A, Anadolu RY, Tutkak H, Gürgey E. HLA-class 1 and class 2 antigens in Turkish patients with pemphigus. International Journal of Dermatology 2002; 41: 79-83.
  • 16. Bilbao JR, Martin-Pagola A, Vitoria JC, Zubillaga P, Ortiz L, Castano L. HLA-DRB1 and MHC class 1 chain-related A haplotypes in Basque families with celiac disease. Tissue Antigens 2002; 601:71-6.
  • 17. Fujiwara H, El Ouriaghli F, Grube M, Price DA, Rezvani K, Gostick E, Sconocchia G, Melenhorst J, Hensel N, Douek DC, Barrett AJ. Identification and in vitro expansion of CD4+ and CD8+ T cells specific for human neutrophil elastase. Blood 2004; 103: 3076-83.
  • 18. Cai J, Lee J, Jankowska-Gan E, Derks R, Pool J, Mutis T, Goulmy E, Burlingham WJ. Minor H Antigen HA-1-specific Regulator and Effector CD8+ T Cells, and HA-1 Microchi merism, in Allograft Tolerance. J Exp Med 2004; 199:1017- 23.
  • 19. Morimoto Y, Toyota M, Satoh A, Murai M, Mita H, Suzuki H, Takamura Y, Ikeda H, Ishida T, Sato N, Tokino T, Imai K. Inactivation of class II transactivator by DNA methylation and histone deacetylation associated with absence of HLA-DR induction by interferon-gamma in haematopoietic tumour cells. Br J Cancer 2004; 90:844-52.
  • 20. Nagore E, Climent J, Planelles MD, Ledesma E, RubioMoscardo F, Fortea JM, Oliver V. Analysis of the CDKN2A and CDK4 genes and HLA-DR and HLA-DQ alleles in two Spanish familial melanoma kindreds. Acta Derm Venereol 2000; 80: 440-2.
  • 21. Andrew McMichael AM, Bowness P. HLA-B27: natural function and pathogenic role in spondyloarthritis. Arthritis Res 2002; Suppl 3: p153-8.
  • 22. Dzuris JL, Sidney J, Horton H, Correa R, Carter D, Chesnut RW, Watkins DI, Sette A. Molecular determinants of peptide binding to two common rhesus macaque major histocompatibility complex class II molecules. J Virol 2001; 75: 10958-68.
  • 23. Hillman GG, Kallinteris NL, Lu X, Wang Y, Wright JL, Li Y, Wu S, Forman JD, Gulfo JV, Humphreys RE, Xu M. Turning tumor cells in situ into T-helper cell-stimulating, MHC class II tumor epitope-presenters: immuno-curing and immuno-consolidation. Cancer Treat Rev 2004; 30: 281-90.
  • 24. Slager EH, Van Der Minne CE, Kruse M, Krueger DD, Griffioen M, Osanto S. Identification of Multiple HLA-DR-Restricted Epitopes of the Tumor-Associated Antigen CAMEL by CD4(+) Th1/Th2 Lymphocytes. J Immunol 2004; 172: 5095-102.
  • 25. Hirose M, Hamano S, Tobinai K, Kuroda Y. Cytocidal activity of PBL, LAK, and IDEC-C2B8 and expression of HLA class 1, ICAM-1, and CD20 in vincristine-resistant hematologic cell lines. J Immunother 1999; 22:237-44.
  • 26. Glimcher LH, Kara CJ. Sequences and factors: a guide to MHC class-II transcription. Annu Rev Immunol 1992; 10:13- 49.
  • 27. Bixby DL, Yannelli JR. CD80 expression in an HLA-A2-positive human non-small cell lung cancer cell line enhances tumor-specific cytotoxicity of HLA-A2-positive T cells derived from a normal donor and a patient with non-small cell lung cancer. Int J Cancer 1998; 78:685-94.
  • 28. McMichael A, Bowness P. HLA-B27: natural function and pathogenic role in spondyloarthritis. Arthritis Res 2002; Suppl 3: p153-8.
  • 29. de Jong MM, Nolte IM, de Vries EG, Schaapveld M, Kleibeuker JH, Oosterom E, Oosterwijk JC, van der Hout AH, van der Steege G, Bruinenberg M, Boezen HM, Te Meerman GJ, van der Graaf WT. The HLA class III subregion is responsible for an increased breast cancer risk. Hum Mol Genet 2003; 12: 2311-9.
  • 30. van Kooij M, de Groot K, van Vugt H, Aten J, Snoek M. Genotype versus phenotype: conflicting results in mapping a lung tumor susceptibility locus to the G7c recombination interval in the mouse MHC class III region. Immunogenetics 2001; 53: 656-61.
  • 31. Zorzetto M, Campo I, Cortelazzo AG, Panelli S, Cuccia M. Improved method for the allelic definition of C4A and C4B polymorphism (HLA class III). Biotechniques 2001; 30: 976-8.

Yıl 2004, Cilt: 2 Sayı: 1, 53 - 57, 01.03.2004

Tahsin Yakut

Öz

Kaynakça

  • 1. Lobo PI, Spencer CE, Isaacs RB, McCullough C. Hyperacute renal allograft rejection from anti-HLA class 1 antibody to B cells--antibody detection by two color FCXM was possible only after using pronase-digested donor lymphocytes. Transpl Int 1997; 10:69-73.
  • 2. Ikuta Y, Katayama N, Wang L, Okugawa T, Takahashi Y, Schmitt M, Gu X, Watanabe M, Akiyoshi K, Nakamura H, Kuribayashi K, Sunamoto J, Shiku H. Presentation of a major histocompatibility complex class 1-binding peptide by monocyte-derived dendritic cells incorporating hydrophobized polysaccharide-truncated HER2 protein complex: implications for a polyvalent immuno-cell therapy. Blood 2002; 99: 3717-24.
  • 3. Dissanayake SK, Thompson JA, Bosch JJ, Clements VK, Chen PW, Ksander BR, Ostrand-Rosenberg S. Activation of tumor-specific CD4(+) T lymphocytes by major histocompatibility complex class II tumor cell vaccines: a novel cell-based immunotherapy. Cancer Res 2004; 64:1867-74.
  • 4. Abbas AK, Lichtman JS. Celluler and molecular immunology. W.B.Saunders, USA. 2nd. edition, 1994; p: 102-14.
  • 5. Doytchinova IA, Guan P, Flower DR. Identifiying human MHC supertypes using bioinformatic methods. J Immunol 2004; 172: 4314-23.
  • 6. Stites DP, Terr AI. Basic and clinical immunology. Stanford, California, 1991.
  • 7. Bainbridge DR, Ellis SA, Sargent IL. HLA-G suppresses proliferation of CD4(+) T-lymphocytes. J Reprod Immunol 2000; 48:17-26.
  • 8. Kim YK, Oh SY, Oh HB, Lee BJ, Son JW, Cho SH, Kim YY, Min KU. Positive association between HLA-DRB1*07 and specific IgE responses to purified major allergens of D. pteronyssinus (Der p 1 and Der p 2). Ann Allergy Asthma Immunol 2002; 88: 170-4.
  • 9. Kudva YC, Deng YJ, Govindarajan R, Abraham RS, Marietta EV, Notkins AL, David CS. HLA-DQ8 transgenic and NOD mice recognize different epitopes within the cytoplasmic region of the tyrosine phosphatase-like molecule, IA-2. Hum Immunol 2001; 62: 1099-105.
  • 10. Weber DA, Dao CT, Jun J, Wigal JL, Jensen PE. Transmembrane domain-mediated colocalization of HLA-DM and HLA-DR is required for optimal HLA-DM catalytic activity. J Immunol 2001; 167: 5167-74.
  • 11. Roitt IM, Jonathan B, Davis MK. Immunology, London, UK, 1993.
  • 12. Matsuzaka Y, Makino S, Nakajima K, Tomizawa M, Oka A, Bahram S, Kulski JK, Tamiya G, Inoko H. New polymorphic microsatellite markers in the human MHC class III region. Tissue Antigens 2001; 57: 397-404.
  • 13. Milner CM, Campbell RD. Genetic organization of the human MHC class III region. Front Biosci 2001; 6 : 914-26.
  • 14. Kostyu DD, Hannick LI, Traweek JL, Ghanayem M, Heilpern D, Dawson DV. HLA class I polymorphism: structure and function and still questions. Hum Immunol 1997: 571: 1- 18.
  • 15. Birol A, Anadolu RY, Tutkak H, Gürgey E. HLA-class 1 and class 2 antigens in Turkish patients with pemphigus. International Journal of Dermatology 2002; 41: 79-83.
  • 16. Bilbao JR, Martin-Pagola A, Vitoria JC, Zubillaga P, Ortiz L, Castano L. HLA-DRB1 and MHC class 1 chain-related A haplotypes in Basque families with celiac disease. Tissue Antigens 2002; 601:71-6.
  • 17. Fujiwara H, El Ouriaghli F, Grube M, Price DA, Rezvani K, Gostick E, Sconocchia G, Melenhorst J, Hensel N, Douek DC, Barrett AJ. Identification and in vitro expansion of CD4+ and CD8+ T cells specific for human neutrophil elastase. Blood 2004; 103: 3076-83.
  • 18. Cai J, Lee J, Jankowska-Gan E, Derks R, Pool J, Mutis T, Goulmy E, Burlingham WJ. Minor H Antigen HA-1-specific Regulator and Effector CD8+ T Cells, and HA-1 Microchi merism, in Allograft Tolerance. J Exp Med 2004; 199:1017- 23.
  • 19. Morimoto Y, Toyota M, Satoh A, Murai M, Mita H, Suzuki H, Takamura Y, Ikeda H, Ishida T, Sato N, Tokino T, Imai K. Inactivation of class II transactivator by DNA methylation and histone deacetylation associated with absence of HLA-DR induction by interferon-gamma in haematopoietic tumour cells. Br J Cancer 2004; 90:844-52.
  • 20. Nagore E, Climent J, Planelles MD, Ledesma E, RubioMoscardo F, Fortea JM, Oliver V. Analysis of the CDKN2A and CDK4 genes and HLA-DR and HLA-DQ alleles in two Spanish familial melanoma kindreds. Acta Derm Venereol 2000; 80: 440-2.
  • 21. Andrew McMichael AM, Bowness P. HLA-B27: natural function and pathogenic role in spondyloarthritis. Arthritis Res 2002; Suppl 3: p153-8.
  • 22. Dzuris JL, Sidney J, Horton H, Correa R, Carter D, Chesnut RW, Watkins DI, Sette A. Molecular determinants of peptide binding to two common rhesus macaque major histocompatibility complex class II molecules. J Virol 2001; 75: 10958-68.
  • 23. Hillman GG, Kallinteris NL, Lu X, Wang Y, Wright JL, Li Y, Wu S, Forman JD, Gulfo JV, Humphreys RE, Xu M. Turning tumor cells in situ into T-helper cell-stimulating, MHC class II tumor epitope-presenters: immuno-curing and immuno-consolidation. Cancer Treat Rev 2004; 30: 281-90.
  • 24. Slager EH, Van Der Minne CE, Kruse M, Krueger DD, Griffioen M, Osanto S. Identification of Multiple HLA-DR-Restricted Epitopes of the Tumor-Associated Antigen CAMEL by CD4(+) Th1/Th2 Lymphocytes. J Immunol 2004; 172: 5095-102.
  • 25. Hirose M, Hamano S, Tobinai K, Kuroda Y. Cytocidal activity of PBL, LAK, and IDEC-C2B8 and expression of HLA class 1, ICAM-1, and CD20 in vincristine-resistant hematologic cell lines. J Immunother 1999; 22:237-44.
  • 26. Glimcher LH, Kara CJ. Sequences and factors: a guide to MHC class-II transcription. Annu Rev Immunol 1992; 10:13- 49.
  • 27. Bixby DL, Yannelli JR. CD80 expression in an HLA-A2-positive human non-small cell lung cancer cell line enhances tumor-specific cytotoxicity of HLA-A2-positive T cells derived from a normal donor and a patient with non-small cell lung cancer. Int J Cancer 1998; 78:685-94.
  • 28. McMichael A, Bowness P. HLA-B27: natural function and pathogenic role in spondyloarthritis. Arthritis Res 2002; Suppl 3: p153-8.
  • 29. de Jong MM, Nolte IM, de Vries EG, Schaapveld M, Kleibeuker JH, Oosterom E, Oosterwijk JC, van der Hout AH, van der Steege G, Bruinenberg M, Boezen HM, Te Meerman GJ, van der Graaf WT. The HLA class III subregion is responsible for an increased breast cancer risk. Hum Mol Genet 2003; 12: 2311-9.
  • 30. van Kooij M, de Groot K, van Vugt H, Aten J, Snoek M. Genotype versus phenotype: conflicting results in mapping a lung tumor susceptibility locus to the G7c recombination interval in the mouse MHC class III region. Immunogenetics 2001; 53: 656-61.
  • 31. Zorzetto M, Campo I, Cortelazzo AG, Panelli S, Cuccia M. Improved method for the allelic definition of C4A and C4B polymorphism (HLA class III). Biotechniques 2001; 30: 976-8.
Toplam 31 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Bölüm Collection
Yazarlar

Tahsin Yakut Bu kişi benim

Yayımlanma Tarihi 1 Mart 2004
Yayımlandığı Sayı Yıl 2004 Cilt: 2 Sayı: 1

Kaynak Göster

APA Yakut, T. (2004). HLA Doku Uygunluk Kompleksi,Genetik Lokalizasyonları ve Fonksiyonları. Güncel Pediatri, 2(1), 53-57.
AMA Yakut T. HLA Doku Uygunluk Kompleksi,Genetik Lokalizasyonları ve Fonksiyonları. Güncel Pediatri. Mart 2004;2(1):53-57.
Chicago Yakut, Tahsin. “HLA Doku Uygunluk Kompleksi,Genetik Lokalizasyonları Ve Fonksiyonları”. Güncel Pediatri 2, sy. 1 (Mart 2004): 53-57.
EndNote Yakut T (01 Mart 2004) HLA Doku Uygunluk Kompleksi,Genetik Lokalizasyonları ve Fonksiyonları. Güncel Pediatri 2 1 53–57.
IEEE T. Yakut, “HLA Doku Uygunluk Kompleksi,Genetik Lokalizasyonları ve Fonksiyonları”, Güncel Pediatri, c. 2, sy. 1, ss. 53–57, 2004.
ISNAD Yakut, Tahsin. “HLA Doku Uygunluk Kompleksi,Genetik Lokalizasyonları Ve Fonksiyonları”. Güncel Pediatri 2/1 (Mart 2004), 53-57.
JAMA Yakut T. HLA Doku Uygunluk Kompleksi,Genetik Lokalizasyonları ve Fonksiyonları. Güncel Pediatri. 2004;2:53–57.
MLA Yakut, Tahsin. “HLA Doku Uygunluk Kompleksi,Genetik Lokalizasyonları Ve Fonksiyonları”. Güncel Pediatri, c. 2, sy. 1, 2004, ss. 53-57.
Vancouver Yakut T. HLA Doku Uygunluk Kompleksi,Genetik Lokalizasyonları ve Fonksiyonları. Güncel Pediatri. 2004;2(1):53-7.